{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,26]],"date-time":"2026-03-26T12:33:53Z","timestamp":1774528433236,"version":"3.50.1"},"reference-count":34,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,3,4]],"date-time":"2022-03-04T00:00:00Z","timestamp":1646352000000},"content-version":"vor","delay-in-days":62,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["IDCases"],"published-print":{"date-parts":[[2022]]},"DOI":"10.1016\/j.idcr.2022.e01467","type":"journal-article","created":{"date-parts":[[2022,3,5]],"date-time":"2022-03-05T02:17:57Z","timestamp":1646446677000},"page":"e01467","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"C","title":["Vaccine hesitancy with a history of Guillain Barre Syndrome: Weighing the risks and benefits of SARS-CoV-2 vaccination"],"prefix":"10.1016","volume":"28","author":[{"given":"Aleksandra","family":"Murawska Baptista","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akankcha","family":"Alok","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Claudia","family":"Libertin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.idcr.2022.e01467_bib1","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1007\/s12016-010-8213-3","article-title":"Guillain-Barr\u00e9 syndrome--a classical autoimmune disease triggered by infection or vaccination","volume":"42","author":"Israeli","year":"2012","journal-title":"Clin Rev Allergy Immunol"},{"issue":"25","key":"10.1016\/j.idcr.2022.e01467_bib2","doi-asserted-by":"crossref","first-page":"1797","DOI":"10.1056\/NEJM199812173392501","article-title":"The Guillain-Barr\u00e9 syndrome and the 1992\u20131993 and 1993\u20131994 influenza vaccines","volume":"339","author":"Lasky","year":"1998","journal-title":"N Engl J Med"},{"key":"10.1016\/j.idcr.2022.e01467_bib3","first-page":"1","article-title":"COVID-19 vaccines and decreased transmission of SARS-CoV-2 [published online ahead of print, 2021 Jul 19]","volume":"29","author":"Vitiello","year":"2021","journal-title":"Inflammopharmacology"},{"key":"10.1016\/j.idcr.2022.e01467_bib4","doi-asserted-by":"crossref","unstructured":"MMWR August 27, 2021\/70(34);1150\u20131155.","DOI":"10.15585\/mmwr.mm7034e1"},{"issue":"34","key":"10.1016\/j.idcr.2022.e01467_bib5","first-page":"1170","article-title":"SARS-CoV-2 infections and hospitalizations among persons aged \u2265\u202f16 years, by vaccination status \u2014 Los Angeles County, California, May 1\u2013July 25, 2021","volume":"70","author":"Griffin","year":"2021","journal-title":"Cent Dis Control Prev"},{"key":"10.1016\/j.idcr.2022.e01467_bib6","article-title":"Guillain-Barr\u00e9 syndrome after COVID-19 vaccination","volume":"14","author":"McKean","year":"2021","journal-title":"BMJ Case Rep CP"},{"issue":"208","key":"10.1016\/j.idcr.2022.e01467_bib7","article-title":"Guillain-Barr\u00e9 syndrome after AstraZeneca COVID-19-vaccination: a causal or casual association","volume":"106887","author":"Introna","year":"2021","journal-title":"Clin Neurol Neurosurg"},{"key":"10.1016\/j.idcr.2022.e01467_bib8","doi-asserted-by":"crossref","first-page":"p312","DOI":"10.1002\/ana.26143","article-title":"Guillain-Barr\u00e9 Syndrome following ChAdOx1-S\/nCoV-19 vaccine","volume":"90","author":"Maramattom","year":"2021","journal-title":"Ann Neurol"},{"key":"10.1016\/j.idcr.2022.e01467_bib9","article-title":"Case of Guillain-Barr\u00e9 syndrome following COVID-19 vaccine","volume":"14","author":"Hasan","year":"2021","journal-title":"BMJ Case Rep CP"},{"key":"10.1016\/j.idcr.2022.e01467_bib10","doi-asserted-by":"crossref","first-page":"4747","DOI":"10.1007\/s10072-021-05467-w","article-title":"A case of acute demyelinating polyradiculoneuropathy with bilateral facial palsy after ChAdOx1 nCoV-19 vaccine","volume":"42","author":"Nasuelli","year":"2021","journal-title":"Neurol Sci"},{"issue":"359","key":"10.1016\/j.idcr.2022.e01467_bib11","article-title":"Sensory Guillain-Barre syndrome following the ChAdOx1 nCov-19 vaccine: report of two cases and review of literature","volume":"577691","author":"Min","year":"2021","journal-title":"J Neuroimmunol"},{"key":"10.1016\/j.idcr.2022.e01467_bib12","doi-asserted-by":"crossref","first-page":"p315","DOI":"10.1002\/ana.26144","article-title":"Guillain\u2013Barr\u00e9 Syndrome Variant occurring after SARS-CoV-2 vaccination","volume":"90","author":"Allen","year":"2021","journal-title":"Ann Neurol"},{"issue":"8","key":"10.1016\/j.idcr.2022.e01467_bib13","doi-asserted-by":"crossref","first-page":"p424","DOI":"10.12691\/ajmcr-9-8-10","article-title":"Guillain-Barr\u00e9 Syndrome in a 67-year-old male post COVID-19 vaccination (Astra Zeneca)","volume":"9","author":"Azam","year":"2021","journal-title":"Am J Med Case Rep"},{"key":"10.1016\/j.idcr.2022.e01467_bib14","article-title":"Guillain-Barre syndrome following the first dose of the chimpanzee adenovirus-vectored COVID-19 vaccine, ChAdOx1","volume":"14","author":"Patel","year":"2021","journal-title":"BMJ Case Rep CP"},{"key":"10.1016\/j.idcr.2022.e01467_bib15","article-title":"Bilateral facial weakness with paraesthesia variant of Guillain-Barr\u00e9 syndrome following Vaxzevria COVID-19 vaccine","author":"Bonifacio","year":"2021","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"360","key":"10.1016\/j.idcr.2022.e01467_bib16","article-title":"AstraZeneca COVID-19 vaccine and Guillain- Barr\u00e9 Syndrome in Tasmania: a causal link?","volume":"577719","author":"Oo","year":"2021","journal-title":"J Neuroimmunol"},{"key":"10.1016\/j.idcr.2022.e01467_bib17","unstructured":"Statement of the WHO Global Advisory Committee on Vaccine Safety (GACVS) COVID-19 subcommittee on reports of Guillain-Barr\u00e9 Syndrome (GBS) following adenovirus vector COVID-19 vaccines. Statement of the WHO Global Advisory Committee on Vaccine Safety (GACVS) COVID-19 subcommittee on reports of Guillain-Barr\u00e9 Syndrome (GBS) following adenovirus vector COVID-19 vaccines; 2021."},{"key":"10.1016\/j.idcr.2022.e01467_bib18","doi-asserted-by":"crossref","unstructured":"Rosenblum HG, Hadler SC, Moulia D., Shimabukuro TT, Su JR, Tepper NK, et al. Use of COVID-19 vaccines after reports of adverse events among adult recipients of Janssen (Johnson & Johnson) and mRNA COVID-19 vaccines (Pfizer-BioNTech and Moderna): update from the advisory committee on immunization practices \u2014 United States, July 2021 | MMWR (cdc.gov), vol. 70(32). CDC; 2021, p. 1094\u20139.","DOI":"10.15585\/mmwr.mm7032e4"},{"issue":"3","key":"10.1016\/j.idcr.2022.e01467_bib19","doi-asserted-by":"crossref","first-page":"p404","DOI":"10.3390\/neurolint13030040","article-title":"A novel case of bifacial diplegia variant of Guillain-Barr\u00e9 syndrome following Janssen COVID-19 vaccination","volume":"13","author":"Prasad","year":"2021","journal-title":"Neurol Int"},{"issue":"22","key":"10.1016\/j.idcr.2022.e01467_bib20","doi-asserted-by":"crossref","first-page":"p1052","DOI":"10.1212\/WNL.0000000000011881","article-title":"Guillain-Barr\u00e9 syndrome in the placebo and active arms of a COVID-19 vaccine clinical trial: temporal associations do not imply causality","volume":"96","author":"Loza","year":"2021","journal-title":"Neurology"},{"issue":"2","key":"10.1016\/j.idcr.2022.e01467_bib21","article-title":"Neurological complications of COVID-19: Guillain-Barre Syndrome following pfizer COVID-19 vaccine","volume":"13","author":"Waheed","year":"2021","journal-title":"Cureus"},{"key":"10.1016\/j.idcr.2022.e01467_bib22","article-title":"Guillain-Barr\u00e9 syndrome after COVID-19 mRNA vaccination in a liver transplant recipient with favorable treatment response","author":"Hughes","year":"2021","journal-title":"Liver Transplant"},{"key":"10.1016\/j.idcr.2022.e01467_bib23","doi-asserted-by":"crossref","first-page":"4093","DOI":"10.1080\/21645515.2021.1954826","article-title":"Electromyoneurography and laboratory findings in a case of Guillain-Barr\u00e9 Syndrome after second dose of Pfizer COVID-19 vaccine","volume":"17","author":"Scendoni","year":"2021","journal-title":"Hum Vaccin Immunother"},{"key":"10.1016\/j.idcr.2022.e01467_bib24","doi-asserted-by":"crossref","first-page":"4401","DOI":"10.1007\/s10072-021-05523-5","article-title":"Guillain-Barr\u00e9 syndrome following BNT162b2 COVID-19 vaccine","volume":"42","author":"Trimboli","year":"2021","journal-title":"Neurol Sci"},{"issue":"230","key":"10.1016\/j.idcr.2022.e01467_bib25","article-title":"Guillain-Barr\u00e9 syndrome is infrequent among recipients of the BNT162b2 mRNA COVID-19 vaccine","volume":"108818","author":"Garc\u00eda-Grimshaw","year":"2021","journal-title":"Clin Immunol"},{"key":"10.1016\/j.idcr.2022.e01467_bib26","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.1001\/jamaneurol.2021.3287","article-title":"Rate of recurrent Guillain-Barr\u00e9 Syndrome after mRNA COVID-19 vaccine BNT162b2","volume":"78","author":"Shapiro Ben David","year":"2021","journal-title":"JAMA Neurol"},{"issue":"5","key":"10.1016\/j.idcr.2022.e01467_bib27","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1080\/20009666.2021.1954284","article-title":"A case of Guillain-Barre syndrome following Pfizer COVID-19 vaccine","volume":"11","author":"Rao","year":"2021","journal-title":"J Community Hosp Intern Med Perspect"},{"issue":"07\u201308","key":"10.1016\/j.idcr.2022.e01467_bib28","doi-asserted-by":"crossref","first-page":"p286","DOI":"10.18071\/isz.74.0286","article-title":"A variant of Guillain-Barre syndrome after SARS-CoV-2 vaccination: AMSAN","volume":"74","author":"Tutar","year":"2021","journal-title":"Ideggy\u00f3gy Szle"},{"issue":"67","key":"10.1016\/j.idcr.2022.e01467_bib29","article-title":"Post-COVID-19 vaccine Guillain-Barr\u00e9 syndrome; first reported case from Qatar","volume":"102540","author":"Razok","year":"2021","journal-title":"Ann Med Surg"},{"key":"10.1016\/j.idcr.2022.e01467_bib30","doi-asserted-by":"crossref","DOI":"10.1002\/ccr3.4756","article-title":"COVID-19 vaccine causing Guillain-Barre syndrome, a rare potential side effect","volume":"9","author":"Matarneh","year":"2021","journal-title":"Clin Case Rep"},{"key":"10.1016\/j.idcr.2022.e01467_bib31","article-title":"Exacerbating Guillain\u2013Barr\u00e9 Syndrome eight days after vector-based COVID-19 vaccination","author":"Finsterer","year":"2021","journal-title":"Hindawi"},{"key":"10.1016\/j.idcr.2022.e01467_bib32","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1007\/s40120-021-00261-4","article-title":"Emerging infection, vaccination, and Guillain\u2013Barr\u00e9 Syndrome: a review","volume":"10","author":"Koike","year":"2021","journal-title":"Neurol Ther"},{"key":"10.1016\/j.idcr.2022.e01467_bib33","doi-asserted-by":"crossref","DOI":"10.1016\/j.clim.2021.108818","article-title":"Guillain-Barr\u00e9 syndrome is infrequent among recipients of the BNT162b2 mRNA COVID-19 vaccine","volume":"230","author":"Garc\u00eda-Grimshaw","year":"2021","journal-title":"Clin Immunol"},{"key":"10.1016\/j.idcr.2022.e01467_bib34","author":"Bertsimas","year":"2020","journal-title":"PLoS One"}],"container-title":["IDCases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2214250922000956?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2214250922000956?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T12:04:16Z","timestamp":1761998656000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2214250922000956"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022]]},"references-count":34,"alternative-id":["S2214250922000956"],"URL":"https:\/\/doi.org\/10.1016\/j.idcr.2022.e01467","relation":{},"ISSN":["2214-2509"],"issn-type":[{"value":"2214-2509","type":"print"}],"subject":[],"published":{"date-parts":[[2022]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Vaccine hesitancy with a history of Guillain Barre Syndrome: Weighing the risks and benefits of SARS-CoV-2 vaccination","name":"articletitle","label":"Article Title"},{"value":"IDCases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.idcr.2022.e01467","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"e01467"}}